louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02323074: Brain Training System Using Electroencephalography (EEG) for Neurorehabilitation of Hand Function After Stroke
Official title: Brain Training System Using Electroencephalography (EEG) for Neurorehabilitation of Hand Function After Stroke
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Stroke
Lead sponsor: Chinese University of Hong Kong
Sponsor class: OTHER
First posted: 2014-12-23
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In this project we will design a control algorithm to identify the focalized motor-related clusters for hand function on each stroke patient. A real-time feedback will control the robotic hand when motor imagery is successfully identified. Finally, the focalized BCI-robot training will be compared in a randomized controlled trial to evaluate the training effectiveness and changes in the EEG patterns.


Eligibility criteria: Inclusion Criteria:

(1) sufficient cognition to follow simple instructions, as well as understand the content and purpose of the experiment (Mini-Mental State Examination (MMSE) score\>25) ; (2) subcortical location of the ischemic lesion within the territory of the middle cerebral artery; (3) have moderate to severe motor disability at the paretic upper limb (assessed by Fugl-Meyer Assessment (FMA), Modified Ashworth Score of fingers (MAS), and Action Research Arm Test (ARAT))

Exclusion Criteria:

(1) severe hand spasticity, open hand wound or hand deformity; (2) visual field deficits; (3) aphasia, neglect, and apraxia.

Primary outcomes:
measure: FMA-UE
timeFrame: 3-month followup
Secondary outcomes:
measure: ARAT
timeFrame: 3-month followup
measure: MAS
timeFrame: 3-month followup
Other outcomes:
Locations:
city: Hong Kong
country: Hong Kong
facility: Division of Biomedical Engineering, Dept Electronic Engineering
Study officials:
References:
Clinical trial NCT06252974: Accurate Diagnosis of the Invasion Depth in ESCC by a Deep Neural Network Analysis of NBI Endoscopy Data
Official title: Accurate Diagnosis of the Invasion Depth in Early Esophageal Squamous Cell Carcinoma by a Deep Neural Network Analysis of Narrow-band Imaging Endoscopy Data
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Esophageal Squamous Cell Carcinoma
Lead sponsor: RenJi Hospital
Sponsor class: OTHER
First posted: 2024-02-12
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Around 500 cases.

Brief summary: The goal of this observational study is to accurate diagnose the stage of esophageal squamous cell carcinoma in order to help physicians to decide the appropriate clinical treatment. The main question it aims to answer is:

• To get early accurate diagnosis of the invasion depth of esophageal squamous cell carcinoma by narrow-band imaging endoscopy data.

Participants' clinical informations from routine examinations and treatments will be collected, there will be no harm to participants.


Eligibility criteria: Inclusion Criteria:

1. Age ≥ 18 years old, regardless of gender;
2. Performing esophageal ESD surgery due to esophageal mucosal lesions;
3. Pathological evaluation of ESD specimens.

Exclusion Criteria:

Pathological examination after ESD surgery ruled out esophageal squamous cell carcinoma.

Primary outcomes:
measure: Accurate diagnose the invasion depth of early esophageal squamous cell carcinoma by endoscopy NBI images through deep neural network analysis
timeFrame: 2024/12/31
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06002074: SMART Program Impact on Quality of Life in Inflammatory Bowel Diseases
Official title: Impact of the Stress Management and Resilience Training (SMART) Program on Quality of Life in Patients with Inflammatory Bowel Diseases
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Inflammatory Bowel Diseases
Stress
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2023-08-21
Enrollment: 17
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: This research study is being done to look at the impact of a Stress Management and Resilience Training (SMART) Program on the quality of life and healthcare utilization of patients with inflammatory bowel disease.


Eligibility criteria: Inclusion Criteria:

* History of IBD defined by a physician global assessment (PGA) of quiescent, mild, moderate, or severe disease.
* Access to internet/device such as smart phone, tablet, or computer
* Patient reports stress as a trigger to their GI symptoms

Exclusion Criteria:

* Corticosteroids in the previous 3 months
* Elicit substance use (including medical marijuana)

Primary outcomes:
measure: Change in Inflammatory Bowel Disease (IBD) Quality of Life (QOL)
timeFrame: Baseline, approximately 20 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic Minnesota
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Victor G. Chedid, M.D., M.S.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00116974: Periodontal Infection and Prematurity Study
Official title: Periodontal Infection and Prematurity Study
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Periodontal Diseases
Premature Birth
Keywords: Dental scaling
Lead sponsor: University of Pennsylvania
Sponsor class: OTHER
First posted: 2005-07-01
Enrollment: 2100
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This research project is a multi-center double-blind, parallel, randomized, controlled clinical trial design comparing the efficacy of dental scaling and root planing to control treatment (superficial cleaning) for the prevention of preterm birth in pregnant women with periodontal disease.


Eligibility criteria: Inclusion Criteria:

* Gestational age between 6 and 20 completed weeks

Exclusion Criteria:

* Periodontal treatment during the pregnancy
* Antibiotic use within 2 weeks of enrollment
* Use of antimicrobial mouthwash within 2 weeks
* Multiple gestation
* Known mitral valve prolapse

Primary outcomes:
measure: Whether screening and treating periodontal disease using scaling and root planing early in pregnancy can reduce the incidence of spontaneous preterm birth <35 weeks
timeFrame: 9 months
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Hospital of the University of Pennsylvania
state: Pennsylvania
Study officials:
affiliation: University of Pennsylvania
name: George A Macones, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Jeffcoat M, Parry S, Sammel M, Clothier B, Catlin A, Macones G. Periodontal infection and preterm birth: successful periodontal therapy reduces the risk of preterm birth. BJOG. 2011 Jan;118(2):250-6. doi: 10.1111/j.1471-0528.2010.02713.x. Epub 2010 Sep 14.
Clinical trial NCT05075174: Effect of Progesterone Levels on 15th Day After Embryo Transfer in Early Miscarriage < 7 WG or Evolving Pregancy Rates
Official title: Effect of Progesterone Levels on 15th Day After Embryo Transfer in Early Miscarriage < 7 WG or Evolving Pregancy Rates
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: ART
Keywords: betaHCG +
pregnancy development know
progesterone level
miscarriage
Lead sponsor: University Hospital, Montpellier
Sponsor class: OTHER
First posted: 2021-10-12
Enrollment: 540
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 43
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: ART program in Montpellier hospital \>18 years old Blood progesterone level 15 days after embryo transfert Pregnancy development know

Brief summary: Progesterone level has been studied at days before embryo transfert. But, progesterone blood level has not been studied 15 days after embryo transfert. The aim of this study is to study progesterone level impact at 15 days after embryo transfert on evolving pregnanies or early miscarriages.


Eligibility criteria: Inclusion criteria:

* ART program in Montpellier hospital
* age \>18 years old
* Blood progesterone level 15 days after embryo transfert
* Pregnancy development know

Exclusion criteria:

- non uterine pregnancy

Primary outcomes:
measure: number of blood progesterone
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Montpellier
country: France
facility: Uhmontpellier
Study officials:
affiliation: University Hospital, Montpellier
name: Noémie Ranisavljevic, M.D., Ph.D
role: STUDY_DIRECTOR
affiliation: University Hospital, Montpellier
name: MARIE DUPORT PERCIER
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04300374: Effects of Remifentanil Infusion on Emergence Delirium After Dental Surgery in Children
Official title: Effects of Remifentanil Infusion on Emergence Delirium After Dental Surgery in Children
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Emergence Delirium
Lead sponsor: Erzincan University
Sponsor class: OTHER
First posted: 2020-03-09
Enrollment: 80
Sex: ALL
Minimum age (years): 2
Maximum age (years): 6
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients between 2 and 6 years old having American Society of Anesthesiologists score 1-2.

Brief summary: In this study, the investigators tried to show the effect of remifentanil on emergence delirium caused by sevoflurane used in general anesthesia.We planned a retrospective study. We formed two groups of 80 participants. One group included patients who were received remifentanil infusion during general anesthesia.The other group included patients who were received only sevoflurane inhalation anesthesia.

The patients included in the study were evaluated for emergence delirium in the postoperative period be evaluating the past recorded informations.


Eligibility criteria: Inclusion Criteria American Society of Anesthesiologists score 1-2

-

Exclusion Criteria:

* neurological disease, psychiatric illness

Primary outcomes:
measure: emergence delirium
timeFrame: 30 minute after operation
Secondary outcomes:
Other outcomes:
Locations:
city: Erzincan
country: Turkey
facility: Nurcan Kutluer Karaca
Study officials:
References:
Clinical trial NCT04231474: Urodynamic Evaluation in Patients After Spinal Cord Injury
Official title: Urodynamic Evaluation Neurgenic Bladder in Patients After Spinal Cord Injury
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Spinal Cord Injuries
Neurogenic Bladder
Urodynamics
Keywords: Urodynamics
Lead sponsor: Poznan University of Medical Sciences
Sponsor class: OTHER
First posted: 2020-01-18
Enrollment: 2
Sex: ALL
Minimum age (years): 30
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Eventually, 54 patients were enrolled in the study (12 women, 42 men). The incompleteness and level of SCI were diagnosed based on MRI, which was performed directly after the injury in Neurosurgery Ward or Trauma Center.

Brief summary: Retrospective study, which analyzed 100 medical histories of patients who were admitted o the Neurological Rehabilitation Ward of the Rehabilitation Clinic in the Orthopedic-Rehabilitation Hospital in Poznan in years 2010-2019.

Detailed description: All patients considered for the study underwent routine testing: blood counts, urinalysis, urine culture, and sensitivity.

Eligibility criteria: Inclusion Criteria:

* incomplete spinal cord injuries,
* the results of the urodynamic testing (conducted by the same urologist) by admission,
* urine culture test by admission.

Exclusion Criteria:

* complete spinal cord injury
* without urodynamic test in medical documentation by admission,
* without urine culture test by admission,
* with symptomatic urinary tract infection in urodynamic test

Primary outcomes:
measure: Urethra sensation
timeFrame: 30 days after spinal injury,
measure: Urethra sensation
timeFrame: after 3 months of rehabilitation
measure: Intravesical pressure
timeFrame: 30 days after spinal injury,
measure: Intravesical pressure
timeFrame: after 3 months of rehabilitation
measure: Bladder complaince
timeFrame: 30 days after spinal injury,
measure: Bladder complaince
timeFrame: after 3 months of rehabilitation
measure: Bladder stability
timeFrame: 30 days after spinal injury,
measure: Bladder stability
timeFrame: after 3 months of rehabilitation
measure: Bladder sensation
timeFrame: 30 days after spinal injury
measure: Bladder sensation
timeFrame: after 3 months of rehabilitation
measure: Bladder capacity
timeFrame: 30 days after spinal injury
measure: Bladder capacity
timeFrame: after 3 months of rehabilitation
measure: Urine volume
timeFrame: 30 days after spinal injury
measure: Urine volume
timeFrame: after 3 months of rehabilitation
Secondary outcomes:
Other outcomes:
Locations:
city: Poznań
country: Poland
facility: Department of Rehabilitation and Physiotherapy Rehabilitation,
Study officials:
affiliation: Clinic Rehabilitation, University of Medical Sciences in Poznań
name: Przemysław Lisiński, MPhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01215474: Pathomolecular Analysis of Rare EGFR Mutations in Advanced NSCLC
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Mutations in Exons 18 to 21
Lead sponsor: Provitro GmbH
Sponsor class: INDUSTRY
Collaborators: name: AstraZeneca
name: Charite University, Berlin, Germany
First posted: 2010-10-06
Enrollment: 500
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who were biopsied and/or received surgery for NSCLC diagnostics

Brief summary: While current mutational analyses comprise exons 19 and 21 in which the majority of EGFR-mutations occur, this study aims at investigating the relevance of exon 18 and 20 mutations. Therefore, the investigators analyse 500 routine tumor samples with respect to the above mentioned exons and correlate the results to the clinical outcome. This approach will enable us to potentially identify patients that might in the future benefit from targeted therapy (EGFR-inhibition).


Eligibility criteria: Inclusion Criteria:

* NSCLC Stadium III-IV

Exclusion Criteria:

* no NSCLC or different stadium

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: Institute of Pathology, Charité University Medicine Berlin
Study officials:
References:
Clinical trial NCT05194774: Greater Trochanter Epiphysiodesis In Hip Pathology
Official title: Outcomes of The Greater Trochanter Epiphysiodesis In Treatment Of Children With Hip Pathology
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Orthopedic Disorder
Lead sponsor: Al-Azhar University
Sponsor class: OTHER
First posted: 2022-01-18
Enrollment: 20
Sex: ALL
Minimum age (years): 5
Maximum age (years): 10
Standard ages: CHILD
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The patients come to the outpatient clinic and underwent clinical and radiological examination will be done , then preparation to surgery by screw

Brief summary: One of the most common problems in the treatment of pediatric patients with various disorders of the hip joint is the formation of deformity of the proximal femur, such as abnormal growth of the greater trochanter, which causes it to be positioned high in relation to the femoral head. This condition is called "relative overgrowth of the greater trochanter" (ROGT).


Eligibility criteria: Inclusion Criteria:

* emerging deformities of the proximal femur with a high position of the greater trochanter, in which its apex was located above the center of the femoral head but below its superior pole; changes in the structure of the femoral neck, accompanied by its shortening; functioning growth zone of the greater trochanter at the time of intervention; and patients without surgical treatment history

Exclusion Criteria:

* hip dislocation upon examination; patients with varus deformity of the femoral neck (neck-shaft angle \<120°), patients with complications of surgical interventions, trauma, rickets, and rheumatoid arthritis; and patients with neurological disorders and Refusal to participate in this study

Primary outcomes:
measure: Radiological measurments
timeFrame: 12 month
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: McCarthy JJ, Weiner DS. Greater trochanteric epiphysiodesis. Int Orthop. 2008 Aug;32(4):531-4. doi: 10.1007/s00264-007-0346-5. Epub 2007 Mar 10.
Clinical trial NCT02113774: The Impact of Antimicrobial Treatment for Asymptomatic Bacteriuria in Renal Transplant Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Urinary Tract Infection
Bacteriuria
Renal Transplantation
Lead sponsor: Rabin Medical Center
Sponsor class: OTHER
First posted: 2014-04-15
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Primary purpose: TREATMENT

Brief summary: The investigators hypothesize that antibiotic therapy for asymptomatic bacteriuria in renal transplant patients does not have impact on the development of symptomatic urinary tract infection (UTI) or progression of renal impairment in patients during the first year after transplantation.


Eligibility criteria: Inclusion Criteria:

* Patients who are ≥1 month and ≤ 12 months after renal transplantation.
* Positive urine culture defined as ≥ 105 colony forming units (CFU) per milliliter of a known single pathogen.

Exclusion Criteria:

* Any one of the following signs and symptoms: fever, abdominal pain, dysuria, frequency, urgency, flank pain, costovertebral-angel tenderness or tenderness over the transplanted kidney
* Active infections in another site
* Leucocytosis (WBC \>18.000K/micl) or leucopenia (WBC \< 3.000 K/micl)
* Elevation of serum creatinine of more than 15% of its baseline level
* Obstructive or other urological complications following transplantation as known foreign device (stent/double-J-Cath, any catheter) in the urinary tract system, known obstruction of the transplanted kidney, indwelling or intermittent catheterization
* Pregnant or lactating women.
* Candidates to invasive urologic procedures.
* Inability to return for regular follow up.
* Previous enrollment in this study.
* Patients who incapable of giving informed consent.

Primary outcomes:
measure: development of symptomatic urinary tract infection
timeFrame: 30 days
Secondary outcomes:
measure: 25% reduction in estimated glomerular filtration rate (eGFR)
timeFrame: 1 year
Other outcomes:
measure: graft loss
timeFrame: 1 year
Locations:
Study officials:
References:
Clinical trial NCT01153074: Bronchoscopic Closure of Bronchopleural Fistulas With Occlutech Figulla ASD N Occluder Device
Official title: Bronchoscopic Closure of Bronchopleural Fistulas With Occlutech Figulla ASD N Occluder Device
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Bronchopleural Fistula
Keywords: Bronchopleural fistula
Bronchoscopy
Lead sponsor: University of Sao Paulo
Sponsor class: OTHER
Collaborators: name: InCor Heart Institute
name: Occlutech International AB
First posted: 2010-06-29
Enrollment: 8
Sex: ALL
Minimum age (years): 14
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the feasibility of closing bronchopleural fistulas with devices originally developed for correction of cardiac septal defects deployed through bronchoscopic procedures.


Eligibility criteria: Inclusion Criteria:

* Patients over 14 years old
* Bronchopleural fistulas

Exclusion Criteria:

* Clinical conditions increasing surgical risk (hemodynamic instability, respiratory distress)
* Immunosuppressed patients
* Acute intense inflammatory process in fistula edge
* Suppurative pleural cavity infection

Primary outcomes:
measure: Closure of tracheobronchial fistulas with the Occlutech Figulla ASD N occluder
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Sao Paulo
country: Brazil
facility: Heart Institute (InCor) Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo
city: Sao Paulo
country: Brazil
facility: Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo
Study officials:
affiliation: Heart Institute (InCor) HC of the Sao Paulo University School
name: Miguel L. Tedde, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Tedde ML, Scordamaglio PR, Rodrigues A, Minamoto H, Alfinito FS. Minimally invasive closure of bronchopleural fistulas. Chest. 2011 Sep;140(3):826. doi: 10.1378/chest.11-0719. No abstract available.
citation: Tedde ML, Minamoto H, Scordamaglio PR, Rodrigues A, Moura EG, Pedra CA. Broncoscopic closure of tracheoesophageal fistulas. Ann Thorac Surg. 2011 Apr;91(4):1311. doi: 10.1016/j.athoracsur.2010.09.015. No abstract available.
citation: Scordamaglio PR, Tedde ML, Minamoto H, Pedra CA, Jatene FB. Endoscopic treatment of tracheobronchial tree fistulas using atrial septal defect occluders: preliminary results. J Bras Pneumol. 2009 Nov;35(11):1156-60. doi: 10.1590/s1806-37132009001100015. English, Portuguese.
citation: Scordamaglio PR, Tedde ML, Minamoto H, Assad RS, Fernandes PMP. Can total bronchopleural fistulas from complete stump dehiscence be endoscopically treated? Eur J Cardiothorac Surg. 2017 Apr 1;51(4):702-708. doi: 10.1093/ejcts/ezw377.
Clinical trial NCT00601874: Bioequivalency Study of 5 mg Pilocarpine Tablets Under Fasting Conditions
Official title: A Single Dose, Two-Treatment, Two-Period, Two Sequence Crossover Bioequivalency Study of 5 mg Pilocarpine Tablets Under Fasting Conditions
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dry Mouth
Lead sponsor: West-Ward Pharmaceutical
Sponsor class: INDUSTRY
First posted: 2008-01-28
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The objective of this study was the bioequivalence of a Roxane Laboratories' Pilocarpine Tablets, 5 mg, to SALAGEN® Tablets, 5 mg (MGI Pharma) under fasting conditions using a single-dose, 2-treatment, 2-period, crossover design.


Eligibility criteria: Inclusion Criteria:

* No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening.

Exclusion Criteria:

* Positive test for HIV, Hepatitis B, or Hepatitis C.
* Treatment with known enzyme altering drugs.
* History of allergic or adverse response to Pilocarpine or any comparable or similar product.

Primary outcomes:
measure: Bioequivalence
timeFrame: Baseline, Two period, Seven day washout
Secondary outcomes:
Other outcomes:
Locations:
city: Austin
country: United States
facility: CEDRA Clinical Research, LLC
state: Texas
Study officials:
affiliation: CEDRA Clinical Research, LLC,
name: Daniel V Freeland, DO
role: PRINCIPAL_INVESTIGATOR
References: